12:15 PM EST - Appili Therapeutics Inc. : Announced positive one-year challenge results from its preclinical study evaluating the efficacy of biodefense vaccine candidate ATI-1701 in a lethal model of tularemia. A survival rate of 29% (n = 2/7) was reported in the ATI-1701 vaccinated cohort, compared to 0% (n = 0/5) in mock vaccinated controls. Appili Therapeutics Inc.
shares T.APLI are trading down $0.01 at $0.19.
